Revolutionary breast cancer therapy: New hope through antibody-active ingredient conjugate
Revolutionary breast cancer therapy: New hope through antibody-active ingredient conjugate
daring breakthrough in breast cancer therapy: Antibody-and-active ingredient conjugate awaken hope! Probably ex -therapy women receive new life perspectives through this groundbreaking treatment!
The shattering numbers speak for themselves: Around 74,500 women in Germany develop breast cancer annually, which makes the disease one of the most common. But now there is light at the end of the tunnel! Experts from the Helios Klinikum Berlin-Buch report sensationally positive results through the use of antibody-active ingredient conjugates. These innovative therapies aim directly at the cancer cells and significantly increase the success of the treatment - a reason for the celebration for many patients!
targeted revolution in treatment
"A real revolution! Nine years after the start of the course, an unbelievable 90 percent of women who have been treated with this means live," emphasizes Prof. Dr. med. Michael Untch, chief physician for obstetrics and gynecology at the Helios Clinic. These patients have already exhausted all other chemotherapeutic options and now owe their survival to this new approach.
But how does this method work? The antibodies in the conjugates tie to antigens on the surface of the tumor cells. In breast cancer, the frequent antigen is the ferment of 25 percent of the patients. After the infusion, the cytotoxic element, which is known as a payload, is transported directly to the cancer cell and triggers cell death there. This revolutionary mechanism could be the beginning of a new life for many women - without cancer!
"At Helios we not only treat breast cancer, but also research solutions for ovarian cancer, cervical cancer, lung cancer and more. The possibilities are limitless," explains Untch. Studies are carried out at five different locations to test the effectiveness and application of this antibody-active ingredient conjugate.
progress against aggressive forms
The high mortality rate for triple-negative breast cancer (TNBC), which affects younger women under the age of 40, is particularly alarming. There are currently only a few therapy options, but here too, two crucial studies are being worked on that use antibody-active ingredient conjugate.Numbers do not lie: Since 2016, more than 41,300 patients have been treated in the Helios clinics. The proportion of men is only 0.9 percent. The trend clearly shows that therapeutic advances in breast cancer control are crucial for a positive future.
To ensure that the patients are well informed as possible, Helios also published educational videos that clarify how early signs of breast cancer can be recognized. A strong step towards more awareness and proactive health care!
Helios is more than just a health service provider-it is an innovation smithy for modern medicine! Every year, over 26 million people opt for treatments in the Helios clinics. The future of breast cancer treatment could therefore be brighter than ever!